Drugs / inupadenant
inupadenant
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05117177 | Jul 2021 → May 2024 | cancer | iTeos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03873883 | Feb 2019 → May 2024 | cancer | iTeos Therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05060432 | Sep 2021 → Jul 2024 | cancer of unknown primary site, head and neck cancer, lung neoplasm, melanoma | iTeos Therapeutics | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05403385 | Aug 2022 → Jun 2025 overdue | non-small cell lung carcinoma | iTeos Therapeutics | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | inupadenant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05060432 ↗ |
| Known as | EOS-105000 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650331 ↗ |
| Known as | EOS100850 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03873883 ↗ |
| Known as | EOS105000 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650331 ↗ |
| Known as | INUPADENANT HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650331 ↗ |
| Action | Inhibit | “investigational adenosine A2A receptor antagonist” NCT05060432 ↗ |
| Modality | Small molecule | — CHEMBL4650331 ↗ |
| Route | Oral | “Oral administration” NCT03873883 ↗ |